SeaStar Medical shares surge 24.78% intraday as Zacks initiates coverage with $12 valuation, citing FDA-approved AKI treatment and positive trials.

SeaStar Medical Holding Corp. surged 24.78% intraday following Zacks Small Cap Research’s initiation of coverage, assigning a $12 valuation and highlighting the company’s FDA-approved QUELIMMUNE™ device for pediatric acute kidney injury (AKI) and its ongoing NEUTRALIZE-AKI trial for adults. The report emphasized the SCD’s first-in-class potential to address cytokine storms in critical care, favorable economics with projected $4.5 billion U.S. AKI market potential, and positive interim trial results. A separate news item underscored the device’s strong clinical outcomes and safety profile, reinforcing investor optimism. These developments align with the stock’s sharp intraday rally, driven by regulatory progress, clinical validation, and a bullish valuation model.